ClinicalTrials.gg

Program

insulin glulisine

Also written as “Insulin Glulisine”, “Insulin glulisine” and “INSULIN GLULISINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 4 companies.

Furthest: phase 4, since Aug 3, 200642 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi380 open or runningphase 4since Aug 3, 2006Sep 20, 2002none ahead
ikfe-CRO20 open or runningphase 4since Aug 15, 2011Aug 15, 2011none ahead
Geropharm10 open or runningphase 3since Jul 9, 2025Jul 9, 2025none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 1since Aug 31, 2009Aug 31, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Sep 20, 2002.

  1. Jan 23, 2008Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT00607087 · 289 enrolled · United States, Australia, Austria and more
  2. Apr 29, 2008Phase 3 study in AMISanofi · NCT00670228 · 34 enrolled · United States, Argentina, Brazil and more
  3. Aug 24, 20092 phase 4 studiesSanofi · NCT00965549, NCT00964574
  4. Aug 31, 2009Profil Institut für Stoffwechselforschung's first study: phase 1 study in Diabetes MellitusNew to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT00969592 · 12 enrolled · Germany
  5. Nov 12, 2009Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01013571 · 493 enrolled · Canada
  6. Feb 25, 2010Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01079364 · 52 enrolled · Netherlands
  7. Jul 8, 2010Phase 1 study in Diabetes Mellitus, Type 2Sanofi · NCT01159353 · 37 enrolled · France
  8. Sep 14, 20104 phase 4 studiesSanofi · NCT01203111, NCT01202474, NCT01204593 and 1 more
  9. Nov 3, 2010Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT01234597 · 219 enrolled · Israel
  10. Aug 15, 2011ikfe-CRO's first study: phase 4 study in Diabetes Mellitus, Type 2New to ikfe-CROikfe-CRO · NCT01417897 · 12 enrolled · Germany
  11. Dec 5, 2011Phase 4 study in Diabetes Mellitus, Type 2ikfe-CRO · NCT01500850 · 60 enrolled · Germany
  12. Sep 20, 2016Phase 1 study in Type1 Diabetes MellitusSanofi · NCT02910518 · 44 enrolled · Germany
  13. Nov 21, 2017Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT03359837 · 384 enrolled · China
  14. Jul 9, 2025Geropharm's first study: phase 3 study in Type 1 Diabetes MellitisNew to GeropharmGeropharm · NCT07070752 · 224 enrolled · Russia

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 42 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07070752Type 1 Diabetes Mellitis · Russia3CompletedGeropharmNov 28, 2023224
NCT03359837Diabetes Mellitus, Type 2 · China4CompletedSanofiJun 29, 2020384
NCT02910518Type1 Diabetes Mellitus · Germany1CompletedSanofiMay 3, 201744
NCT01500850Diabetes Mellitus, Type 2 · Germany4UNKNOWNikfe-CROOct 201260
NCT01417897Diabetes Mellitus, Type 2 · Germany4UNKNOWNikfe-CROMay 201212
NCT01234597Diabetes Mellitus, Type 2 · Israel4CompletedSanofiApr 2015219
NCT01212913Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedSanofiMay 2012161
NCT01204593Diabetes Mellitus, Type 1 · Algeria, Argentina, Brazil and more4CompletedSanofiJan 2013206
NCT01203111Diabetes Mellitus, Type 2 · Algeria, Brazil, Israel and more4CompletedSanofiJul 2012207
NCT01202474Diabetes Mellitus, Type 1 · Russian Federation4CompletedSanofiOct 2012100
NCT01159353Diabetes Mellitus, Type 2 · France1CompletedSanofiApr 200837
NCT01079364Diabetes Mellitus, Type 2 · Netherlands4TerminatedSanofiJul 201252
NCT01013571Diabetes Mellitus, Type 2 · Canada4CompletedSanofiJan 2012493
NCT00969592Diabetes Mellitus · Germany1CompletedProfil Institut für StoffwechselforschungDec 200712
NCT00965549Diabetes Mellitus, Type 2 · Australia, United Kingdom4CompletedSanofiDec 2012463
NCT00964574Diabetes Mellitus, Type 1 · Belarus4CompletedSanofiJul 201068
NCT00670228AMI · United States, Argentina, Brazil and more3TerminatedSanofiNov 200934
NCT00607087Diabetes Mellitus, Type 1 · United States, Australia, Austria and more4CompletedSanofiJun 2009289
NCT00539448Diabetes Mellitus, Type 1 · Bahrain, Kuwait, Qatar and more4CompletedSanofiDec 200898
NCT00526513Diabetes Mellitus · Egypt4CompletedSanofiMay 2008188
NCT00489190Diabetes Mellitus, Type 1 · Kazakhstan4CompletedSanofi45
NCT00467376Diabetes Mellitus · China3CompletedSanofiJun 2008485
NCT00397553Diabetes Mellitus, Type 1 · Russian Federation3CompletedSanofiDec 2007104
NCT00384085Diabetes Mellitus, Type 2 · United States4CompletedSanofiMar 2010588
NCT00368394Diabetes Mellitus, Type 1 · Germany1CompletedSanofi18
NCT00360698Diabetes Mellitus, Type 2 · United States, Russian Federation, United Kingdom4CompletedSanofiAug 2008106
NCT00311077Diabetes Mellitus1CompletedSanofiOct 2004
NCT00310297Diabetes Mellitus, Type 21CompletedSanofiDec 2004
NCT00297583Diabetes Mellitus, Type 11CompletedSanofiMay 2004
NCT00290979Diabetes Mellitus, Type 1 · Japan3CompletedSanofi250
NCT00290927Diabetes Mellitus, Type 2 · Japan3CompletedSanofi390
NCT00290043Diabetes Mellitus, Type 11CompletedSanofi20
NCT00272064Diabetes Mellitus, Type 2 · Italy3CompletedSanofiMay 2008352
NCT00272012Diabetes Mellitus, Type 2 · Germany3CompletedSanofiSep 2006396
NCT00271284Diabetes Mellitus, Type 1 · France3CompletedSanofiSep 200888
NCT00174668Diabetes Mellitus, Type 2 · Australia, Belgium, Czech Republic and more3CompletedSanofiNov 2007311
NCT00135941Diabetes Mellitus · United States3CompletedSanofi582
NCT00135096Diabetes Mellitus, Type 2 · United States3CompletedSanofi345
NCT00135083Diabetes Mellitus, Type 23CompletedSanofi347
NCT00135057Diabetes Mellitus, Type 2 · United States3CompletedSanofi281
NCT00115570Diabetes Mellitus, Type 1 · United States3CompletedSanofiNov 2006572
NCT00046150Diabetes Mellitus, Type 1 · France, Germany, Netherlands3CompletedSanofi59

How it is read

Names in the registry

  • “Insulin Glulisine”, 12 entries
  • “Insulin glulisine”, 11 entries
  • “insulin glulisine”, 8 entries
  • “INSULIN GLULISINE”, 4 entries
  • “INSULIN GLULISINE (HMR1964)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.